Pulmonx Corporation’s Post

BLVR impact on cardiac function: A single-center, non-randomized, prospective study showed significant clinical improvements in cardiac preload, myocardial contractility and cardiac output for patients with severe #COPD/#emphysema without a history of cardiovascular disease.* Read more: https://bit.ly/3ESBsTD #BLVR #Bronchoscopy #MedDevice #Pulmonology

Accurate. Comprehensive. Actionable #HeartFlow

Emergency departments often see an uptick in visits over the holiday season. For patients experiencing chest pain or other cardiac symptoms, PATHFAST delivers critical lab-quality results in minutes at the point of care,  with a comprehensive menu of cardiac tests including Tnl, NT-proBNP and D-Dimer. Learn how the PATHFAST Cardiac Biomarker Analyzer helps busy facilities boost efficiency here: https://lnkd.in/eZMM7ttS * Oudin A, Bjursten H, et al. Impact of national holidays and weekends on incidence of acute type A aortic dissection repair. Sci Rep. 2022;12(1):20552. doi:10.1038/s41598-022-25076-7

Challenging Case Osteal and Distal #Leftmain with thrombotic Occlusion of CX 81 old Patient was admitted by #NSTEM, no Cardiac Diseases in History, Coronary Angiography shows thrombotic occlusion of CX and significant ostial and distal #Leftmain Stenosis.successfully CX Recanalisation and #DKCrush Technique in Leftmain with final POT with good final Result #PCI #Cathlab #interventionalcardiology #DKCrush

The JSCAI Special Issue on The Role of Cardiac Computed Tomography Angiography in Diagnosis, Treatment, and Prognosis of Cardiac Disease is now available! This issue highlights the broad spectrum of clinical and practical uses for #CCTA. Explore the Special Issue ➡️ https://lnkd.in/gxK9Ss5t

ECGs recorded during cardiac stress tests, whether functional or pharmacological, show essential data relating to arrhythmias, coronary artery blockages, valve problems, and other issues affecting the patient's cardiovascular health. #GEHealthCare#StressTest#Cardiology

This study reinforces the overall safety of the PPSV23 pneumonia vaccine, in an evaluation of the association between cardiovascular, neurological, and immunological adverse events and PPSV23 in older adults using a self-controlled risk interval design. https://ja.ma/3SrfFd0

Cardiovascular disease (CVD) is the leading cause of death globally, and the prevalence is expected to continue rising as people live longer and the population increases. Early detection of heart disease is critical to improving patient outcomes, but providing rapid echocardiographic assessments at the point of care can be difficult in resource-constrained facilities and practices. GE HealthCare today announced the launch of Caption AI-driven software for rapid cardiac assessments at the point of care on Vscan Air SL. Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings. 🌐⇢ https://lnkd.in/dtQiVngP

Cardiovascular disease (CVD) is the leading cause of death globally, and the prevalence is expected to continue rising as people live longer and the population increases. Early detection of heart disease is critical to improving patient outcomes, but providing rapid echocardiographic assessments at the point of care can be difficult in resource-constrained facilities and practices. GE HealthCare today announced the launch of Caption AI-driven software for rapid cardiac assessments at the point of care on Vscan Air SL. Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings. 🌐⇢ https://lnkd.in/dtQiVngP

Patients with a small annulus in the aortic valve of the heart – the ring-like base of the valve that supports its leaflets – face challenges when undergoing transcatheter aortic valve replacement (TAVR). These patients, many of them women, are at greater risk for a host of poor outcomes. Now, the largest, randomized, controlled TAVR trial to primarily enroll women has some answers to address this. Results of the SMART trial, comparing self-expanding and balloon-expandable TAVR valves in patients with a small annulus, were recently published in the New England Journal of Medicine, with UH Harrington Heart & Vascular Institute’s Guilherme Attizzani, MD, Interventional Director of the Valve and Structural Heart Disease Center, as study co-author and steering committee member. Dr. Attizzani also holds the Alexander and Marianna McAfee Endowed Chair in Innovative Cardiovascular Intervention. SMART trial results show advantages for the self-expanding valve – already in regular use at UH for patients with a small annulus. But Dr. Attizzani says the study is likely to have wide impact elsewhere and cause clinicians who haven’t typically used these devices to take a second look. Read more at https://lnkd.in/gzz42n9v #TAVR #SMARTtrial #womenshealth #hearthealth #physicianexcellence #patientsfirst